Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -11.21 | — | — | — | — | — | 0.24 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 25.61 | — | — | — | — | — | 1.69 | 2.96 | 1.93 | 1.60 | 2.95 | 2.15 | 5.47 | 7.41 | 8.29 | 16.47 | 17.70 | 18.79 | 38.46 | 126.13 | — |
| — | — | — | — | — | — | -42.8% | +37.3% | -64.7% | -78.5% | -64.4% | -86.9% | -69.1% | -60.6% | -78.5% | -86.9% | — | — | — | +3230.5% | — | |
| P/B Ratio | 1.68 | 2.08 | 2.06 | 1.23 | 0.84 | 0.75 | 0.22 | 1.63 | 0.81 | 0.50 | 0.70 | 0.52 | 1.10 | 1.40 | 1.33 | 2.17 | 1.78 | 2.38 | 2.85 | 3.70 | 4.06 |
| — | +176.4% | +845.5% | -24.7% | +3.4% | +50.0% | -68.8% | +215.0% | -26.7% | -64.2% | -47.6% | -76.2% | -37.9% | -41.1% | -53.2% | -41.2% | -56.2% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | -0.61 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.4% | — | — | — | — | — | 89.4% | -109.1% | -49.8% | -124.5% | -166.1% | -116.5% | -111.2% | -125.3% | 91.0% | 95.8% | 86.0% | 90.1% | 92.2% | 100.0% | — |
| — | — | — | — | — | — | +153.8% | +6.3% | +55.3% | +0.6% | -282.6% | -221.7% | -229.3% | -239.1% | -1.4% | -4.2% | — | — | — | 0.0% | — | |
| Operating Margin | -1601.1% | — | — | — | — | — | -213.0% | -261.8% | -186.0% | -252.2% | -364.5% | -280.0% | -299.5% | -315.1% | -286.8% | -296.0% | -354.2% | -534.2% | -598.8% | -1594.5% | — |
| — | — | — | — | — | — | +41.6% | +6.5% | +37.9% | +20.0% | -27.1% | +5.4% | +15.4% | +41.0% | +52.1% | +81.4% | — | — | — | -2756.2% | — | |
| Net Margin | -288.3% | — | — | — | — | — | 1021.9% | -252.4% | -174.0% | -236.0% | -341.7% | -257.2% | -273.6% | -289.8% | -259.5% | -266.2% | -341.0% | -531.5% | -600.7% | -1599.0% | — |
| — | — | — | — | — | — | +399.1% | +1.8% | +36.4% | +18.6% | -31.7% | +3.4% | +19.8% | +45.5% | +56.8% | +83.4% | — | — | — | -2891.3% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -21.8% | -11.1% | -17.6% | -15.8% | -10.8% | -26.7% | 53.3% | -30.1% | -17.0% | -17.2% | -18.7% | -14.6% | -13.1% | -13.0% | -10.0% | -8.5% | -10.4% | -15.7% | -10.6% | -11.1% | -132.4% |
| — | +58.4% | -133.0% | +47.4% | +36.6% | -55.1% | +384.9% | -106.8% | -30.1% | -33.0% | -86.9% | -71.4% | -25.4% | +17.3% | +5.8% | +23.7% | +92.1% | — | — | — | — | |
| ROA | -18.6% | -10.4% | -16.0% | -14.6% | -10.2% | -25.4% | 48.0% | -23.4% | -13.4% | -13.7% | -15.0% | -12.0% | -11.2% | -11.2% | -8.6% | -7.4% | -9.0% | -13.5% | -9.2% | -9.8% | -95.5% |
| — | +59.2% | -133.3% | +37.5% | +23.8% | -85.0% | +419.4% | -95.9% | -19.5% | -22.8% | -75.1% | -62.6% | -25.0% | +17.2% | +7.1% | +24.9% | +90.6% | -27.5% | +71.1% | -123.0% | — | |
| ROIC | -139.1% | -15.2% | -19.6% | -17.1% | -20.0% | -385.8% | -121.4% | -44.5% | -25.8% | -30.5% | -35.9% | -28.2% | -23.2% | -16.4% | -10.8% | -14.8% | -81.2% | — | — | — | — |
| — | +96.1% | +83.9% | +61.5% | +22.4% | -1163.3% | -237.8% | -57.9% | -11.3% | -85.6% | -234.1% | -90.6% | +71.5% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
| — | — | — | — | — | — | — | +31.8% | +18.6% | +19.9% | +19.7% | +14.8% | +13.8% | -31.3% | +128.0% | +136.5% | +150.5% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.26 | 17.38 | 11.36 | 10.26 | 16.76 | 20.41 | 18.95 | 3.59 | 4.89 | 4.20 | 5.16 | 4.72 | 6.48 | 11.15 | 9.29 | 9.56 | 10.61 | 9.87 | 11.78 | 9.90 | 14.01 |
| — | -14.8% | -40.1% | +185.9% | +242.7% | +385.9% | +267.2% | -24.0% | -24.5% | -62.3% | -44.5% | -50.6% | -39.0% | +13.0% | -21.1% | -3.5% | -24.2% | +2639.8% | +2452.4% | +1493.3% | — | |
| Quick Ratio | 10.26 | 17.38 | 11.36 | 10.26 | 16.76 | 20.41 | 18.95 | 3.28 | 4.54 | 3.92 | 4.86 | 4.48 | 6.30 | 10.89 | 9.08 | 9.46 | 10.57 | 9.81 | 11.77 | 9.90 | 14.01 |
| — | -14.8% | -40.1% | +213.1% | +268.8% | +420.0% | +289.8% | -26.8% | -27.9% | -64.0% | -46.4% | -52.7% | -40.4% | +10.9% | -22.8% | -4.5% | -24.5% | +2623.8% | +2448.6% | +1493.3% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | -283.55 | -250.43 | -314.33 | -284.42 | -280.07 | -308.84 | -261.47 | -243.25 | -248.55 | -313.83 | -237.91 | -279.53 | -553.70 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying WHWK stock.
Whitehawk Therapeutics Inc's current P/E is -11.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Whitehawk Therapeutics Inc's current operating margin is -1601.1%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Whitehawk Therapeutics Inc's business trajectory between earnings reports.